A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
LUMIBIRD operates in the Medical - Diagnostics & Research industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 224M | 224M | 221M | 201M | 192M | 146M |
| Net Income | 6.2M | 6.2M | 7.7M | 12M | 16M | 6.5M |
| EPS | $0.28 | $0.28 | $0.35 | $0.54 | $0.73 | $0.34 |
| Free Cash Flow | 37M | 37M | 22M | 1.5M | 31M | 15M |
| ROIC | 8.0% | 3.1% | 4.0% | 6.4% | 8.1% | 3.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.77 | 0.71 | 0.30 | 0.60 | 0.51 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 12M | 12M | 13M | 18M | 23M | 9.9M |
| Operating Margin | 5.6% | 5.6% | 6.0% | 9.0% | 11.8% | 6.8% |
| ROE | 2.9% | 2.9% | 3.7% | 5.7% | 8.1% | 3.4% |
| Shares Outstanding | 22M | 22M | 22M | 22M | 22M | 19M |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 146M | 192M | 201M | 221M | 224M | 224M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 9.9M | 23M | 18M | 13M | 12M | 12M |
| Op. Margin | 6.8% | 11.8% | 9.0% | 6.0% | 5.6% | 5.6% |
| Net Income | 6.5M | 16M | 12M | 7.7M | 6.2M | 6.2M |
| Net Margin | 4.4% | 8.5% | 5.9% | 3.5% | 2.7% | 2.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 3.9% | 8.1% | 6.4% | 4.0% | 3.1% | 8.0% |
| ROE | 3.4% | 8.1% | 5.7% | 3.7% | 2.9% | 2.9% |
| ROA | 1.8% | 4.3% | 3.0% | 1.9% | 1.4% | 1.3% |
| Cash Flow | ||||||
| Op. Cash Flow | 15M | 31M | 1.5M | 22M | 37M | 37M |
| Free Cash Flow | 15M | 31M | 1.5M | 22M | 37M | 37M |
| Owner Earnings | 4.3M | 17M | -14M | 5.4M | 17M | 17M |
| CapEx | 0 | 0 | 0 | 0 | 0 | 0 |
| Maint. CapEx | 11M | 14M | 15M | 17M | 20M | 20M |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | 0 |
| D&A | 11M | 14M | 15M | 17M | 20M | 20M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 3.1M | 310K | 926K | 3.4M | 768K | 768K |
| Buyback Yield | 1.0% | 0.1% | 0.2% | 1.1% | 0.4% | 0.2% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 4.4M | 21M | 20M | 24M | 78M | 78M |
| Balance Sheet | ||||||
| Net Debt | 4.2M | 13M | -3.1M | 89M | 88M | -77M |
| Cash & Equiv. | 92M | 115M | 65M | 61M | 77M | 77M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.51 | 0.60 | 0.30 | 0.71 | 0.77 | 0.00 |
| Interest Coverage | N/A | N/A | 5.2 | 2.9 | 1.8 | 1.8 |
| Equity | 188M | 214M | 204M | 210M | 214M | 214M |
| Total Assets | 351M | 410M | 392M | 440M | 464M | 464M |
| Total Liabilities | 162M | 196M | 188M | 230M | 250M | 250M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 121M | 147M | 71M | 134M | 140M | 140M |
| Current Assets | 186M | 216M | 197M | 214M | 225M | 225M |
| Current Liabilities | 66M | 68M | 126M | 80M | 86M | 86M |
| Per Share Data | ||||||
| EPS | 0.34 | 0.73 | 0.54 | 0.35 | 0.28 | 0.28 |
| Owner EPS | 0.23 | 0.77 | -0.61 | 0.24 | 0.80 | 0.80 |
| Book Value | 10.03 | 9.57 | 9.15 | 9.42 | 9.77 | 9.77 |
| Cash Flow/Share | 0.80 | 1.40 | 0.07 | 1.01 | 1.70 | 1.18 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 18.8M | 22.4M | 22.3M | 22.3M | 21.9M | 21.9M |
| Valuation | ||||||
| P/E Ratio | 47.5 | 35.1 | 31.4 | 38.8 | 35.6 | 78.7 |
| P/FCF | 20.4 | 18.3 | 249.5 | 13.4 | 5.9 | 13.0 |
| EV/EBIT | 31.3 | 26.0 | 20.5 | 29.4 | 24.5 | 32.6 |
| Price/Book | 1.6 | 2.7 | 1.8 | 1.4 | 1.0 | 2.3 |
| Price/Sales | 2.1 | 3.0 | 1.9 | 1.4 | 1.0 | 2.2 |
| FCF Yield | 4.9% | 5.5% | 0.4% | 7.5% | 17.0% | 7.7% |
| Market Cap | 307M | 575M | 375M | 300M | 219M | 484M |
| Avg. Price | 12.82 | 20.28 | 20.33 | 16.23 | 11.65 | 22.10 |
| Year-End Price | 16.36 | 25.71 | 16.84 | 13.47 | 9.99 | 22.10 |
LUMIBIRD passes 1 of 9 quality checks, indicating weak fundamentals.
LUMIBIRD trades at 78.7x trailing earnings, compared to its 15-year median P/E of 35.6x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 13.0x vs a median of 15.8x. The company's 5-year average ROIC is 5.1%. Total shareholder yield (buybacks) is 0.2%. At current prices, the estimated annualized return to fair value is +8.5%.
LUMIBIRD (LBIRD-PA) has a current P/E ratio of 78.7, compared to its historical median P/E of 35.6. The stock is currently considered Expensive based on its historical valuation range.
LUMIBIRD (LBIRD-PA) has a 5-year average return on invested capital (ROIC) of 5.1%. This is below average and may indicate limited pricing power.
LUMIBIRD (LBIRD-PA) has a market capitalization of $484M. It is classified as a small-cap stock.
LUMIBIRD (LBIRD-PA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.16%.
Based on historical P/E analysis, LUMIBIRD (LBIRD-PA) appears expensive. The current P/E of 78.7 is 121% above its historical median of 35.6. The estimated fair value CAGR (P/E method) is -1.7%.
LUMIBIRD (LBIRD-PA) operates in the Medical - Diagnostics & Research industry, within the Healthcare sector.
LUMIBIRD (LBIRD-PA) reported annual revenue of $224 million in its most recent fiscal year, based on SEC EDGAR filings.
LUMIBIRD (LBIRD-PA) has a net profit margin of 2.7%. This is a modest margin.
LUMIBIRD (LBIRD-PA) generated $37 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
LUMIBIRD (LBIRD-PA) has a debt-to-equity ratio of 0.77. This indicates moderate leverage.
LUMIBIRD (LBIRD-PA) reported earnings per share (EPS) of $0.28 in its most recent fiscal year.
LUMIBIRD (LBIRD-PA) has a return on equity (ROE) of 2.9%. This indicates moderate shareholder returns.
The Ledger Terminal provides 5 years of financial data for LUMIBIRD (LBIRD-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LUMIBIRD (LBIRD-PA) has a book value per share of $9.77, based on its most recent annual SEC filing.
No recent items.